


Public private partnership



This graphic above shows connections between the Gates Foundation, Wellcome Trust, WHO, GAVI and other NGOs and Big Pharma... It contains round about 6500 objects including like Persons, NGOs, Companies, Documents, etc. It also includes more than 7200 links between them.

All information is publicly available.

The following slides presents some selected organizations from this graphic. Cause of the complexity it shows mostly only the first level of connection.

First, you will get some general information about people from government agencies, companies and non-governmental organizations, as well as some important events or groups. Further on in this document you will find a link analysis of these "stakeholders".

The red lines are always payments, but there might be also some black lines are payments as well. Please see link description.


Please make your own opinion and do your own research!

2021-09-12

YGL -
Young
Global
Leaders

BMGF -
Bill & Melinda
Gates
Foundation

Grants from BMGF, Wellcome Trust and OP



Total Grants by Bill & Melinda Gates Foundation (1994-2021) - Top 50 Rows

3	Sum of AMOUNT COMMITTED	
4	GRANTEE COUNTRY	Total
5	United States	43,496,475,796,00
6	Switzerland	13,106,637,833,00
7	United Kingdom	2,953,403,252,00
8	India	1,253,951,882,00
9	Kenya	1,188,788,307,00
10	Nigeria	887,239,968,00
11	Canada	769,413,724,00
12	South Africa	589,111,107,00
13	Pakistan	434,859,991,00
14	Germany	434,000,105,00
15	France	425,882,803,00
16	Netherlands	422,472,922,00
17	Mexico	416,769,415,00
18	China	395,422,490,00
19	Australia	336,284,180,00
20	Korea, Republic of	330,309,122,00
21	Belgium	309,496,035,00
22	Japan	290,231,477,00
23	Italy	261,121,430,00
24	Saudi Arabia	253,298,091,00
25	Philippines	220,706,845,00
26	Bangladesh	175,982,296,00
27	Congo	134,798,309,00
28	Norway	130,695,672,00
29	Côte d'Ivoire	122,098,648,00
30	Uganda	119,041,383,00
31	Peru	117,830,886,00
32	Spain	116,992,589,00
33	Tanzania, United Republic of	113,471,411,00
34	Ethiopia	113,140,040,00
35	Indonesia	113,109,445,00
36	United Arab Emirates	107,986,151,00
37	Senegal	103,098,579,00
38	Singapore	92,601,478,00
39	Ghana	91,705,501,00
40	Denmark	68,758,093,00
41	Thailand	64,054,043,00
42	Colombia	56,910,013,00
43	Finland	52,305,171,00
44	Malaysia	51,596,329,00
45	Zimbabwe	44,380,389,00
46	Brazil	44,344,138,00
47	Viet Nam	34,676,543,00
48	Sweden	33,880,117,00
49	Turkey	33,134,337,00
50	Poland	30,000,094,00
51	Lithuania	28,852,353,00
52	Zambia	28,451,800,00
53	Mauritius	24,092,449,00
54	Burkina Faso	22,336,886,00
55		22,065,038,00
56	Israel	21,194,906,00
57	Latvia	20,242,121,00
58	Chile	19,960,075,00
59	Rwanda	16,232,978,00

3	Row Labels	Sum of AMOUNT COMMITTED
4	GAVI Alliance	4,949,056,550,00
5	World Health Organization	3,382,840,574,00
6	The Global Fund to Fight AIDS, Tuberculosis and Malaria	2,998,391,281,00
7	PATH	2,578,300,627,00
8	University of Washington Foundation	1,376,710,904,00
9	United Negro College Fund, Inc.	1,338,312,107,00
10	The Rotary Foundation of Rotary International	1,285,286,700,00
11	United States Fund for UNICEF	1,143,667,405,00
12	The GAVI Campaign	1,137,924,663,00
13	International Bank for Reconstruction and Development	1,126,822,007,00
14	Johns Hopkins University	742,059,691,00
15	MMV Medicines for Malaria Venture	726,814,710,00
16	Alliance for a Green Revolution in Africa	638,359,987,00
17	Clinton Health Access Initiative Inc	544,166,541,00
18	Aeras	513,993,536,00
19	Foundation for the National Institutes of Health (FNIH)	504,887,034,00
20	Global Alliance for TB Drug Development Inc	476,021,941,00
21	New Venture Fund	419,530,642,00
22	Hispanic Scholarship Fund	419,110,327,00
23	International AIDS Vaccine Initiative (IAVI)	412,901,894,00
24	CARE	410,167,727,00
25	Emory University	387,854,910,00
26	UNICEF Headquarters	382,653,424,00
27	United Nations Foundation	363,530,983,00
28	Centro Internacional de Mejoramiento de Maiz y Trigo	360,843,458,00
29	Population Services International	352,941,086,00
30	PATH Vaccine Solutions	343,795,819,00
31	Duke University	326,168,706,00
32	World Health Organization Nigeria Country Office	319,456,633,00
33	University of Manitoba	315,966,351,00
34	London School of Hygiene and Tropical Medicine	305,031,150,00
35	Imperial College London	303,563,584,00
36	Harvard University	298,632,120,00
37	University of Washington	281,914,723,00
38	University of California San Francisco	280,217,094,00
39	Gates Medical Research Institute	276,968,362,00
40	Family Health International	266,536,106,00
41	Cornell University	259,876,471,00
42	International Food Policy Research Institute	256,163,096,00
43	University of Oxford	254,033,626,00
44	Islamic Development Bank	246,108,304,00
45	University of Maryland, Baltimore	245,788,209,00
46	Save the Children Federation, Inc.	244,266,744,00
47	International Vaccine Institute	242,583,242,00
48	World Health Organization Pakistan Country Office	242,356,566,00
49	Columbia University	240,570,937,00
50	The One Campaign	237,469,429,00
51	Global Alliance for Improved Nutrition	235,688,678,00
52	Fred Hutchinson Cancer Research Center	230,704,021,00
53	Cambridge University Development Office in the United States Inc (CUDOUS)	229,449,000,00
54	JSI Research & Training Institute, Inc.	219,074,687,00
55	FHI Solutions LLC	217,951,412,00
56	The Carter Center	215,818,664,00
57	International Development Association	199,732,953,00
58	FUND	199,240,310,00


3	Row Labels	Sum of AMOUNT COMMITTED
4	Global Development	21,314,936,294,00
5	Global Health	18,397,247,482,00
6	U.S. Program	9,159,238,029,00
7	Global Growth & Opportunity	7,567,844,633,00
8	Global Policy and Advocacy	4,705,588,960,00
9	Global Development Global Health	2,952,537,749,00
10	Executive	1,626,410,176,00
11	Executive U.S. Program	1,276,629,387,00
12	Global Development Global Policy and Advocacy	827,940,424,00
13	Global Development Global Health Global Policy and Advocacy	520,217,014,00
14	Global Development Global Growth & Opportunity	431,529,680,00
15	Communications Global Development Global Health Global Policy and Advocacy	311,630,758,00
16	Finance and Resource Planning Global Development	308,296,430,00
17	Finance and Resource Planning	264,503,250,00
18	Gender Equality	263,558,725,00
19	Global Policy and Advocacy U.S. Program	238,618,319,00
20	Global Growth & Opportunity Global Policy and Advocacy	157,803,334,00
21	Global Development Global Growth & Opportunity Global Health	147,910,332,00
22	Global Health Global Policy and Advocacy	111,391,622,00
23	Gender Equality Global Development Global Growth & Opportunity Global Health Global Policy and Advocacy	96,408,608,00
24	Gender Equality Global Development	91,754,347,00
25	Foundation Strategy Office	83,796,745,00
26	Gender Equality Global Development Global Health Global Policy and Advocacy	80,929,595,00
27	Global Development Global Growth & Opportunity Global Health Global Policy and Advocacy	74,211,934,00
28	Global Growth & Opportunity Global Health	60,644,183,00
29	Executive Global Health	52,524,087,00
30	Gender Equality Global Growth & Opportunity Global Policy and Advocacy	27,220,184,00
31	Global Development Global Growth & Opportunity Global Policy and Advocacy	25,933,179,00
32	Finance and Resource Planning Global Growth & Opportunity	25,000,000,00
33	Foundation Strategy Office Global Development Global Health	24,140,000,00
34	Gender Equality Global Growth & Opportunity	15,434,354,00
35	Gender Equality Global Policy and Advocacy	11,471,796,00
36	Executive Global Development	10,479,708,00
37	Executive Gender Equality Global Development	10,287,499,00
38	Executive Global Development Global Growth & Opportunity	10,000,000,00
39	Communications Global Policy and Advocacy	8,847,821,00
40	Foundation Strategy Office Global Development Global Growth & Opportunity Global Health Global Policy and Advocacy	8,074,000,00
41	Foundation Strategy Office Global Development	7,581,352,00
42	Executive Global Development Global Growth & Opportunity Global Policy and Advocacy	6,998,115,00
43	Executive Global Policy and Advocacy	6,625,000,00
44	Executive Gender Equality	6,202,113,00
45	Gender Equality Global Development Global Health	5,684,278,00
46	Gender Equality Global Development Global Policy and Advocacy	5,595,280,00
47	Communications	5,449,165,00
48	Gender Equality Global Development Global Growth & Opportunity	4,817,705,00
49	Executive Global Growth & Opportunity	3,500,013,00
50	Global Growth & Opportunity Global Health Global Policy and Advocacy	2,099,891,00
51	Global Health U.S. Program	1,925,000,00
52	Gender Equality Global Development Global Growth & Opportunity Global Health	1,115,582,00
53	Global Growth & Opportunity U.S. Program	733,477,00
54	Foundation Strategy Office Gender Equality	569,234,00
55	Gender Equality Global Health	566,176,00
56	Communications Global Development	199,754,00
57	Foundation Strategy Office Global Health	187,672,00
58	Executive Global Development Global Health	153,208,00

Overview

Bill & Melinda Gates Foundation, Wellcome Trust, Rockefeller Foundation, World Economic Forum	6
GAVI, CEPI, COVAX, Find, The Global Fund	12
Direct Grants to Swiss Agency for Therapeutic Products, Charite, RKI - Robert Koch Institut, MHRA – Medicines & Healthcare products regulatory Agency and European Commission	23
Direct Grants to World Bank Group and KFW (Link Analysis)	28
Some “Public Websites”	33
Link Analysis	48
Link Analysis – Selected Views	81
IT	96
“EXERCISES”	99
“Meetings”	113
“Gang”	116
Sample of Public Private Partnership - Open Letter to Biden Administration – 3rd August 2021	125
Media	132
Misc	136
“Selected Person”	139

Bill & Melinda Gates Foundation (BMGF)

Direct connections (extract of entire link analysis)



Details you'll find in separate file: CorinaNetwork_GatesFoundationOnlyDirectConnections_2021-09-12.png

https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation

<https://www.gatesfoundation.org/>

<https://www.gatesfoundation.org/about/financials>

<https://www.gatesfoundation.org/about/committed-grants>

<https://www.gatesfoundation.org/philanthropypartners>

<https://www.gatesfoundation.org/goalkeepers/>

Bill & Melinda Gates Foundation Strategic Investment FUND

Portfolio (extract):


	1mg Technologies Private Limited 1mg Technologies Private Limited is a digital consumer healthcare platform in India that provides online-to-offline services to help customers access medicines, diagnostics, and tele-consultations. The foundation invested in the Company to accelerate low-cost delivery of high-quality essential medicines and other Read More
	Abbott Laboratories Abbott Laboratories received support from the foundation to make its Panbio COVID-19 Ag Rapid Test available to low- and middle-income countries. Making high-quality, affordable rapid diagnostic tests with results available in 15-20 minutes is critical in the fight to control Read More
	Achaogen Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation's investment is supporting the development of Achaogen's monoclonal antibody ("mAb") discovery platform. Press Release
	Acrobatiq The foundation invested in Acrobatiq, a leader in adaptive learning solutions, to support the growth of a next-generation adaptive learning, courseware, and analytics program. Press Release
	Adjuvant Global Health Technology Fund The foundation has committed to further support the Global Health Investment Fund model by investing as an anchor LP in Adjuvant. Adjuvant is a private investment fund focused on late-stage life sciences investments to address global health challenges. The Fund invests Read More
	Affinivax Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine. News Story
	Africa Health Fund The foundation invested in the Africa Health Fund to provide capital to support new approaches to improving the quality and accessibility of private healthcare across the continent.
	African Agricultural Capital Fund The African Agricultural Capital Fund provides growth capital to companies that boost the productivity and profitability of smallholder farmers in East Africa. Press Release
	African Leadership Fund The African Leadership Foundation is a U.S. 501(c)(3) organization with a mission to educate Africa's next generation of young leaders. The foundation provided a loan to support the organization's 2020-2021 school year objectives. Investment Date: May 2020
	AgBiome AgBiome is focused on discovery and development of biological and transgenic products for crop protection. AgBiome identifies microbes from a wide variety of sources to harness their natural abilities to help crops resist pests and stresses. Press Release

	BioE Pharmaceutical company Biological E identifies innovative approaches to reduce the cost of vaccine production. Press Release News Story
	BioNTech BioNTech is focused on combining ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The Foundation is working with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and tuberculosis infection as Read More Press Release
	bKash Through its mobile payments platform, bKash helps to ensure access to a broader range of financial services for the people of Bangladesh. Press Release News Story
	BloomBoard Software development company BloomBoard received funding from the foundation to help efforts in improving teachers' instructional practices. Press Release
	Butterfly Network Butterfly has created the world's first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation's vision of an ecosystem where hardware, software, data and expertise come together Read More Press Release News Story
	CHAI (Clinton Health Access Initiative) The foundation provided a guarantee to CHAI to structure volume guarantees to reduce the price and increase access to life-saving commodities in the developing world.
	Charter School Growth Fund Facility Fund The Charter School Growth Fund provides strategic support to high-performing charter management organizations. Inclusive within its support, CSGF provided subordinated bridge loans to address the short-term financing gap CMOs face during construction.
	Charter School Growth Fund Facility Fund III As a follow-on to the CSGF Facility Fund, the organization created a new fund in 2016, to broaden their lending to include early-stage operators, provide more proactive technical assistance and partner with other key stakeholders to remove barriers to affordable charter facilities and financing.
	Civic Builders Funding from the foundation and New Markets Tax Credits, alongside support from Civic Builders, built new schools in a bankrupt city where facilities assistance was otherwise unavailable. Case Study
	ClinVet ClinVet specializes in conducting clinical trials to understand and improve veterinary health products. With the help of the foundation, ClinVet was able to construct a new facility in Morocco to expand its capabilities to conduct trials for livestock products.

	LumiraDx LumiraDx develops point-of-care diagnostics solutions on a portable, cloud-connected reader using finger-prick blood samples tested on disposable, microfluidic strips. The company is working to achieve lab-quality performance and health+IT integration at point-of-care settings globally. The foundation invested in the company Read More
	Lyndra Therapeutics Lyndra Therapeutics is developing an orally administered dosage form designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. The foundation invested in the company to Read More Press Release
	M-KOPA M-KOPA is a Nairobi-based, off-grid solar energy company, which makes residential power systems affordable and accessible to low-income, off-grid customers through a mobile payment-based lease-to-own model. Press Release Case Study
	Medical Credit Fund (MCF) The Medical Credit Fund provides loans and technical assistance to small primary care clinics in Africa. Through the loan fund, MCF expanded its lending and technical assistance across Ghana, Nigeria, Kenya, and Tanzania. Press Release
	Merck The foundation partnered with private and public organizations make Implanon NXT®, a single rod, long-acting, reversible contraceptive implant, available in the world's poorest countries at a more than 50 percent price reduction. Press Release Case Study
	Mylan Dolutegravir Mylan Laboratories, along with Aurobindo Pharma, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price. Press Release News Story
	OraSure The foundation invested in OraSure to secure a reduced price for the saliva-based HIV self-test OraQuick. Press Release News Story
	Owl Ventures Owl Ventures is a venture investment fund that leads Series A/B investments in US K-12 education technology companies.
	PAHO The Pan American Health Organization (PAHO) is an international public health agency working to improve health and living standards in America.
	Pfizer The foundation invested in Pfizer to expand access to the pharmaceutical company's all-in-one injectable contraceptive, Sayana, giving women in the developing world an affordable option.

Wellcome Trust


Direct connections (extract of entire link analysis)



<https://wellcome.org>
https://en.wikipedia.org/wiki/Wellcome_Trust

Rockefeller Foundation

Here you can see only a small excerpt of the Rockefeller Foundation. The Rockefeller Foundation's connections are actually much more far-reaching. No connections to other Rockefeller NGOs, such as Rockefeller Philanthropy Advisors, Rockefeller Brothers Fund, etc. are shown here.



World Economic Forum (WEF)

“The World Economic Forum

The World Economic Forum is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas.

It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. Moral and intellectual integrity is at the heart of everything it does.

Our activities are shaped by a unique institutional culture founded on the stakeholder theory, which asserts that an organization is accountable to all parts of society. The institution carefully blends and balances the best of many kinds of organizations, from both the public and private sectors, international organizations and academic institutions.


We believe that progress happens by bringing together people from all walks of life who have the drive and the influence to make positive change.

Read the latest Annual Report [here](#). Find out about our Foundation [Regulations](#) and [Statutes](#).”

<https://www.weforum.org/about/world-economic-forum>

“World Economic Forum Partners are leading global companies developing solutions to the world’s greatest challenges. They are the driving force behind the Forum’s programmes. Our Partners engage in Forum Platforms to shape the future, accessing networks and experts to ensure strategic decision-making on the most pressing world issues.”


<https://www.weforum.org/partners>



<https://intelligence.weforum.org/topics/a1G0X000006O6EHUA0?tab=publications>

World Economic Forum (WEF)

Direct connections
(extract of entire link analysis)



GAVI, officially Gavi, the Vaccine Alliance

(previously the **GAVI Alliance**, and before that the **Global Alliance for Vaccines and Immunization**)

“GAVI facilitates vaccinations in developing countries by working with donor governments, the [World Health Organization](#),^[4] [UNICEF](#),^[5] the [World Bank](#),^[6] the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the [Bill & Melinda Gates Foundation](#)^[7] and other private philanthropists. GAVI has observer status at the [World Health Assembly](#).”

<https://en.wikipedia.org/wiki/GAVI>


„Die Impfallianz Gavi wurde am 29. Januar 2000 am **Weltwirtschaftsforum (WEF – World Economic Forum)** in **Davos** ins Leben gerufen. “

<https://www.savethechildren.de/news/20-jahre-im-einsatz-fuer-kinder-die-impfallianz-gavi/>



<https://www.gavi.org/our-alliance/about>

GAVI - Direct connections (extract of entire link analysis)



GAVI has full immunity in Switzerland

Abkommen

zwischen dem **Schweizerischen Bundesrat** und **GAVI Alliance** (Global Alliance for Vaccines and Immunization) zur Regelung des rechtlichen Statuts von GAVI Alliance in der Schweiz

<https://www.fedlex.admin.ch/eli/cc/2009/541/de>

(Stand am 1. Januar 2009)

¹ Der Originaltext findet sich unter der gleichen Nummer in der französischen Ausgabe dieser Sammlung.

Der Schweizerische Bundesrat

einerseits

und

GAVI Alliance (Global Alliance for Vaccines and Immunization)

andererseits,

in dem Wunsche, ihre Beziehungen in einem Sitzabkommen zu regeln,

sind wie folgt übereingekommen:

- **I. Statut, Vorrechte und Immunitäten von GAVI Alliance**

- **Art. 1 Persönlichkeit und Rechtsfähigkeit**

Der Schweizerische Bundesrat anerkennt die internationale Rechtspersönlichkeit und die Rechtsfähigkeit von GAVI Alliance in der Schweiz.

- **Art. 2 Unabhängigkeit und Handlungsfreiheit**

1. Der Schweizerische Bundesrat garantiert GAVI Alliance Unabhängigkeit und Handlungsfreiheit.

2. Er gewährt ihr die uneingeschränkte Versammlungsfreiheit, einschliesslich der Rede-, Beschluss- und Publikationsfreiheit, auf dem Hoheitsgebiet der Schweiz.

- **Art. 3 Unverletzbarkeit der Räumlichkeiten**

Die Gebäude oder Gebäudeteile und das anliegende Gelände, die von GAVI Alliance für ihre eigenen Zwecke benützt werden, sind ungeachtet der herrschenden Eigentumsverhältnisse unverletzbar. Kein Vertreter schweizerischer Behörden darf sie ohne ausdrückliche Zustimmung des Exekutivdirektors von GAVI Alliance oder der von ihm bezeichneten Person betreten.

- **Art. 4 Unverletzbarkeit der Archive**

Die Archive von GAVI Alliance und alle ihr gehörenden oder in ihrem Besitz befindlichen Dokumente und Datenträger ganz allgemein sind jederzeit und überall unverletzbar.

- **Art. 5 Immunität von der Gerichtsbarkeit und der Vollstreckung**

1. Im Rahmen ihrer Tätigkeit geniesst GAVI Alliance Immunität von der Gerichtsbarkeit und der Vollstreckung, ausser:

- a) wenn diese Befreiung im Einzelfall vom Exekutivdirektor oder durch die von ihm bezeichnete Person ausdrücklich aufgehoben worden ist;
- b) im Falle einer gegen GAVI Alliance angestregten zivilrechtlichen Haftungsklage wegen eines Schadens, der durch ein GAVI Alliance gehörendes oder auf ihre Rechnung betriebenes Kraftfahrzeug verursacht wurde;
- c) im Falle einer durch richterlichen Entscheid angeordneten Beschlagnahme von Gehältern, Löhnen und anderen Bezügen, welche GAVI Alliance einem ihrer Beamten schuldet;
- d) im Falle einer Widerklage, die in unmittelbarem Zusammenhang mit einer von GAVI Alliance erhobenen Hauptklage steht; und
- e) im Falle der Vollstreckung einer schiedsrichterlichen Entscheidung, welche in Anwendung von Artikel 29 dieses Abkommens gefällt wurde.

2. Die Gebäude oder Gebäudeteile, das anliegende Gelände sowie die Vermögenswerte, die sich im Eigentum von GAVI Alliance befinden oder von ihr zu ihren Zwecken benutzt werden, sind unabhängig von ihrem Standort und ihrem Besitzer befreit von:

- a) jeglicher Form von Requisition, Beschlagnahme oder Enteignung;
- b) jeglicher Form von Zwangsvollstreckung, anderen behördlichen Zwangsmassnahmen oder Massnahmen, die einem Urteil vorausgehen, mit Ausnahme der in Absatz 1 vorgesehenen Fälle.

- **Art. 6 Veröffentlichungen und Mitteilungen**

CEPI - Coalition for Epidemic Preparedness Innovations

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.


To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome.

<https://cepi.net/about/whoweare/>



CEPI launches at 2017
Davos Meeting

CEPI - Coalition for Epidemic Preparedness Innovations




CEPI - Coalition for Epidemic Preparedness Innovations

This link analysis shows direct path of people are shown in previous graph.

Please have a look at separate file:

Corina_Network_CEPI_PeopleAndThei
rDirectPath_2021-09-12.png



FIND

“FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world.

We connect countries and communities, funders, decisionmakers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems.

We are working to save 1 million lives through accessible, quality diagnosis, and save US\$1 billion in healthcare costs to patients and health systems. We are co-convenor of the [Access to COVID-19 Tools \(ACT\) Accelerator](#) diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic”


<https://www.finddx.org/about/>

<https://www.finddx.org/>

<https://dndi.org/press-releases/2010/international-status-granted/>

https://en.wikipedia.org/wiki/Foundation_for_Innovative_New_Diagnostics

FIND



COVAX / ACT-A

COVAX

With a fast-moving pandemic, no one is safe, unless everyone is safe

COVAX is co-led by CEPI, Gavi and WHO, alongside key delivery partner UNICEF. In the Americas, the PAHO Revolving Fund is the recognized procurement agent for COVAX.

CEPI

Gavi
The Vaccine Alliance

unicef

World Health
Organization

<https://www.who.int/initiatives/act-accelerator/covax>

<https://www.gavi.org/vaccineswork/covax-explained>

<https://en.wikipedia.org/wiki/COVAX>

2,2 Milliarden Euro für Impfungen, Diagnostik und Medikamente


Die Pandemie kann nur besiegt werden, wenn sie weltweit unter Kontrolle gebracht wird: Deutschland hat sich deshalb schon früh für eine gemeinsame und solidarische Antwort auf die Pandemie stark gemacht. Nach dem Grundsatz „Niemand ist sicher, bis alle sicher sind“ hat Deutschland im vergangenen Jahr den Koordinierungsmechanismus Access to Covid-19 Tools Accelerator (ACT-A) mitgegründet. Als derzeit zweitgrößter Geber von ACT-A hat Deutschland bislang 2,2 Milliarden Euro zur Verfügung gestellt. Der Großteil der Unterstützung geht an die internationale Impfstoffplattform COVAX, ein Teil wird auch für Diagnostik und Medikamente gegen die Krankheit verwendet. Bis Anfang August wurden dadurch bereits 138 Staaten mit insgesamt über 200 Millionen Dosen der Impfstoffe von AstraZeneca, Johnson & Johnson, Moderna und BioNTech versorgt.

Auszug aus <https://www.auswaertiges-amt.de/de/aussenpolitik/themen/gesundheits/covax/2395748> vom 26.08.2021

Weiterführende Links:

<https://www.who.int/initiatives/act-accelerator>

<https://www.gavi.org/covax-facility>



The Global Fund

„Der **Globale Fonds zur Bekämpfung von AIDS, Tuberkulose und Malaria** ([englisch](#) **The Global Fund to Fight AIDS, Tuberculosis and Malaria**, kurz GFATM) mit Sitz in [Genf](#), [Schweiz](#), ist ein Finanzierungsinstrument zur Bekämpfung der drei großen Infektionskrankheiten [AIDS](#), [Tuberkulose](#) und [Malaria](#). Der weltweit in mehr als 100 Ländern tätige Fonds ist eines der wichtigsten Instrumente zur Bekämpfung dieser Krankheiten.“

„Der Fonds wurde im Jahr 2002 gegründet, nachdem sich die [G8-Staaten](#) auf ihrem [Treffen in Genua 2001](#) darauf verständigt hatten, die Finanzierung des weltweiten Kampfes gegen die drei schweren Infektionskrankheiten AIDS, Tuberkulose und Malaria zu verstärken. Schon ein Jahr zuvor forderte der ehemalige [UN-Generalsekretär Kofi Annan](#) die Einrichtung eines solchen Fonds^[2]. Der Fonds dient der Finanzierung nationaler Maßnahmen gegen die drei Krankheiten einschließlich der Stärkung von Gesundheitssystemen. Er fördert zudem die Eigenverantwortung der Regierungen, die Mitwirkung der Zivilgesellschaft und des privaten Sektors sowie wirkungs- und genderorientierte Maßnahmen gegen Aids, Tuberkulose und Malaria. Der ehemalige Leiter des US-AIDS-Programms PEPFAR (President's Emergency Plan for AIDS Relief), Mark Dybul, wurde im Jahre 2012 zum Leiter des Globalen Fonds gewählt. Er hatte dieses Amt bis Mai 2017 inne. Mark Dybul gilt in Fachkreisen als Visionär im Bereich globaler Gesundheit und hatte maßgeblich an der Gründung und Durchführung des Notfallplans des US-Präsidenten für AIDS-Bekämpfung (PEPFAR) beigetragen. Als Arzt mit dem Schwerpunkt Immunologie wurde er als Mediziner, Wissenschaftler und strategisch denkender Verwalter zum ausgewiesenen HIV- und AIDS-Experten. Nach dem Abschied von Mark Dybul leitete Marijke Wijnroks vorübergehend die Organisation. Seit März 2018 ist [Peter Sands](#) Direktor des GFATM.“

„Deutschland und der Globale Fonds
Als viertgrößter Geber (nach den USA, Frankreich und Großbritannien) leistet Deutschland einen bedeutenden Beitrag zur weltweiten Bekämpfung von AIDS, Tuberkulose und Malaria.^[13] Zudem spielt das Land als Mitglied des Verwaltungsrats eine entscheidende Rolle dabei, den globalen Fonds bei der Umstrukturierung und Straffung von dessen Betriebsabläufen zu unterstützen, damit die Investitionen der Organisation durchdacht getätigt werden und auf maximale Wirkung ausgerichtet sind. Außerdem hat der Fonds ein neues Finanzierungsmodell eingeführt. Durch das neue Finanzierungsmodell wird eine stärkere Verantwortung der Länder für Projekte gefördert. Zudem wirkt das neue Finanzierungsmodell als Anreiz für politischen Dialog mit den Programmdurchführungsländern und zielt gleichzeitig auf die Berücksichtigung von Themen der Gleichberechtigung von Männern und Frauen sowie der sexuellen und reproduktiven Gesundheit und von Menschenrechtsbelangen ab. Der Landesdialog als Schlüsselement des neuen Finanzierungsmodells bietet außerdem neue Chancen für das Engagement aller Partner, auch aus der Zivilgesellschaft und der freien Wirtschaft. Neben diesen Beiträgen ist Deutschland auch einer der führenden Schirmherren des Programms Debt2Health des Globalen Fonds, das weltweit zu einem erheblichen Anstieg der Förderung von Programmen des Globalen Fonds geführt hat. Im Rahmen dieser Initiative hat Deutschland in Ländern wie Côte d'Ivoire, Indonesien, Pakistan und Ägypten einen Schuldenschnitt vorgenommen.“

https://de.wikipedia.org/wiki/Global_Fund

https://en.wikipedia.org/wiki/The_Global_Fund_to_Fight_AIDS,_Tuberculosis_and_Malaria

<https://www.theglobalfund.org/en/overview/>

<https://www.theglobalfund.org/en/>

<https://www.theglobalfund.org/en/board/>

<https://www.theglobalfund.org/en/private-ngo-partners/resource-mobilization/bill-melinda-gates-foundation/>



Direct grants from Bill & Melinda Gates Foundation (BMGF) to

- Swiss Agency for Therapeutic Products, Switzerland
- Charite, Germany
- RKI - Robert Koch Institut, Germany
- MHRA – Medicines & Healthcare products regulatory Agency, United Kingdom
- European Commission

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending



GRANTEE Swiss Agency for Therapeutic Products	DIVISION Global Health	DATE FEBRUARY 2020	REGION SERVED GLOBAL +1	COMMITTED AMOUNT \$900,000
	GRANT TOPIC Development of Solutions to Improve Global Health	DURATION (MONTHS) 46	GRANTEE LOCATION Berne, Switzerland	
GRANTEE Swiss Agency for Therapeutic Products	DIVISION Global Health	DATE DECEMBER 2015	REGION SERVED GLOBAL +1	COMMITTED AMOUNT \$1,332,000
	GRANT TOPIC Development of Solutions to Improve Global Health	DURATION (MONTHS) 67	GRANTEE LOCATION Berne, Switzerland	
GRANTEE Swiss Agency for Development and Cooperation	DIVISION Global Growth & Opportunity	DATE SEPTEMBER 2010	REGION SERVED GLOBAL +2	COMMITTED AMOUNT \$453,381
	GRANT TOPIC Water, Sanitation and Hygiene	DURATION (MONTHS) 48	GRANTEE LOCATION Bern, Switzerland	

<https://www.gatesfoundation.org/about/committed-grants?q=Swiss%20Agency>
<https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/internationale-zusammenarbeit/multilaterale-zusammenarbeit-mit-internationalen-organisationen-/bill-and-melinda-gates-foundation.html>

Show 10

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	MARCH 2020	GLOBAL	\$249,550
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Support Innovative Technology Solutions	40	Berlin, Germany	

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	DECEMBER 2019	GLOBAL	\$86,181
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Pneumonia	4	Berlin, Germany	

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Policy and Advocacy	OCTOBER 2018	GLOBAL	\$549,999
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Global Health and Development Public Awareness and Analysis	14	Berlin, Germany	

<https://www.gatesfoundation.org/about/committed-grants?q=Charit%C3%A9>

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Robert Koch Institute	Global Health	NOVEMBER 2019	GLOBAL	\$253,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Vaccine Development	59	Berlin, Berlin, Germany	

Show 10

<https://www.gatesfoundation.org/about/committed-grants?q=robert%20koch>

MHRA awarded over £980,000 for collaboration with the Bill and Melinda Gates Foundation and the World Health Organisation

MHRA today announced a partnership worth over £980,000 to improve the safety monitoring of medicines in low and middle-income countries.

From: [Medicines and Healthcare products Regulatory Agency](#)
Published 15 December 2017



We are delighted to announce a new partnership with the Bill & Melinda Gates Foundation and the World Health Organisation that aims to extensively improve the safety monitoring of medicines in low and middle-income countries (LMIC).

New medicines and vaccines, for diseases such as malaria and HIV, may be introduced for the first time in LMIC's where there are weak or no regulatory

<https://www.gov.uk/government/news/mhra-awarded-over-980000-for-collaboration-with-the-bill-and-melinda-gates-foundation-and-the-world-health-organisation>

Related content

[Report of the Commission on Human Medicines Expert Working Group on Optimising Data on Medicines used During Pregnancy](#)

[Report of the Commission on Human Medicines' Expert Working Group on Hormone Pregnancy Tests](#)

[Safer Medicines in Pregnancy and Breastfeeding Consortium](#)

[Epilepsy medicines and pregnancy](#)

Brexit

[Check what you need to do](#)

MHRA and the Bill & Melinda Gates Foundation to look at the safer, effective use of medicines during pregnancy

MHRA and the Bill & Melinda Gates Foundation have begun new research on medicine use which could impact the health of pregnant women around the world.

From: [Medicines and Healthcare products Regulatory Agency](#)
Published 17 September 2019



In advance of World Patient Safety Day (17 September), MHRA specialists, as part of a broader programme of work, have begun developing ground-breaking research to support the safer use of medicine during pregnancy.

A \$360,000 grant over two years from the Bill & Melinda Gates Foundation (approximately £292,000), will support the MHRA's research, to help predict the need for adjusting a medicine's dose during different trimesters of pregnancy. This will ensure effective use, which is vitally important for the health of mother and baby.

Worldwide, data in this area remain limited, and new insights could potentially impact the health of pregnant women around the world. This would also give obstetricians further clarity on the optimal dose of a

<https://www.gov.uk/government/news/mhra-and-the-bill-melinda-gates-foundation-to-look-at-the-safer-effective-use-of-medicines-during-pregnancy>

Brexit

[Check what you need to do](#)

Committed Grants; sort by Date Descending

Date Descending



GRANTEE European Commission	DIVISION Global Development	DATE MARCH 2020	REGION SERVED GLOBAL ⁺¹	COMMITTED AMOUNT \$500,000
	GRANT TOPIC Nutrition	DURATION (MONTHS) 17	GRANTEE LOCATION Brussels, Belgium	
GRANTEE European Commission	DIVISION Global Health	DATE MARCH 2019	REGION SERVED GLOBAL ⁺¹	COMMITTED AMOUNT \$45,178,000
	GRANT TOPIC Development of Solutions to Improve Global Health	DURATION (MONTHS) 238	GRANTEE LOCATION Brussels, Belgium	
GRANTEE European Centre for Development Policy Management	DIVISION Global Policy and Advocacy	DATE MARCH 2017	REGION SERVED GLOBAL	COMMITTED AMOUNT \$399,982
	GRANT TOPIC Global Health and Development Public Awareness and Analysis	DURATION (MONTHS) 25	GRANTEE LOCATION Maastricht, Netherlands	
GRANTEE European Commission	DIVISION Global Development	DATE FEBRUARY 2016	REGION SERVED GLOBAL ⁺²	COMMITTED AMOUNT \$500,000
	GRANT TOPIC Nutrition	DURATION (MONTHS) 22	GRANTEE LOCATION Brussels, Belgium	
GRANTEE Imperial College London	DIVISION Global Growth & Opportunity	DATE SEPTEMBER 2010	REGION SERVED GLOBAL ⁺¹	COMMITTED AMOUNT \$2,692,835
	GRANT TOPIC Agricultural Development	DURATION (MONTHS) 40	GRANTEE LOCATION London, United Kingdom	

<https://www.gatesfoundation.org/about/committed-grants?q=european%20commission>

World Bank - Partners



<https://www.worldbank.org/en/topic/financialinclusion/overview#4>

https://www.globalfinancingfacility.org/sites/gff_new/files/documents/GFF-IG1-2_Participant%20List_2025.pdf

CONTEXT

STRATEGY


RESULTS

PARTNERS


The World Bank Group works globally with standard-setting bodies to develop guidelines, standards and good practices. We also work with the G20 to develop guidance for regulators and policymakers and to catalyze new actions in support of financial inclusion. We are also an implementing partner for the G20 Global Partnership for Financial Inclusion (GPFI).


We also work closely with a number of organizations and donor partners to advance financial inclusion, including Alliance for Financial Inclusion (AFI), AusAid, the Bill and Melinda Gates Foundation, DFID, Financial Sector Development Trusts, GIZ, the Ministry of Foreign Affairs of the Netherlands, the OECD, SECO, UNCDF, UNCITRAL, UNSGSA, USAID, and regional development banks.

The Ministry of Foreign Affairs of the Netherlands and the Bill and Melinda Gates Foundation provide the funding for the Financial Inclusion Support Framework (FISF), while SECO provides funding for the Consumer Protection and Financial Literacy (CPFL) program, and DFID provides funding for the Harnessing Innovation for Financial Inclusion (HiFi) program.



IFC International Finance Corporation (World Bank)





Some “Public Websites”

Please look at the people and organizations.

You’ll find some of them later in several link analysis.

Mai 2017 / August 2018

Four new members complete the International Advisory Board on Global Health

<https://www.bundesgesundheitsministerium.de/english-version/press/2018/international-advisory-board.html>



Meeting in July with some members of the IAB and two Secretary of States (from left to right: Farrar, Roses, Hacker, Kickbusch, Secretary of State Stroppe, Nishtar, Elias, Schneider, Secretary of State Flachsbarth, Benn)

The Advisory Board consists of ten German and international experts. Six members of the International Advisory Board on Global Health have already been appointed by the Federal Ministry of Health in August 2017. Another four were appointed as members in May 2018. The Board now includes experts from different regions and stakeholder groups that have extensive expertise on various global health topics.

Members of the International Advisory Board on Global Health

- Prof Dr Ilona Kickbusch, Director of the Global Health Centre at the Graduate Institute of International and Development Studies, Geneva (Chair of the board)
- Prof Dr Christian Drosten, Chair of the Institute of Virology at the Charité Berlin
- Dr Christopher Elias, President of the Global Development Program, Bill & Melinda Gates Foundation
- Dr Jeremy Farrar, Director of the Wellcome Trust
- Prof Dr Jörg Hacker, President of the German National Academy of Sciences Leopoldina
- Dr Matshidiso Rebecca Moeti, WHO Regional Director for Afrika
- Dr Mirta Roses Periago, former Director of the Pan American Health Organization
- Dr Sania Nishtar, President of Heartfile
- Dr Gisela Schneider, Director of the German Institute for Medical Mission
- Dr Christonh Benn, Director for External Relations of the Global Fund to Fight AIDS.

Mai 2018

WHO Global Preparedness Monitoring Board

The Global Preparedness Monitoring Board is a joint arm of the WHO and the World Bank.

Created in response to recommendations by the UN Secretary General's [Global Health Crises Task Force in 2017](#), the GPMB was co-convened by the World Health Organization and the World Bank Group and formally launched in May 2018

<https://apps.who.int/gpmb/>

Co-chairs

Board Members

Co-conveners



Dr Victor Dzau

President of the US National Academy of Medicine, USA




Dr Chris Elias

President, Global Development Program, Bill & Melinda Gates Foundation, USA



Sir Jeremy Farrar

Director, Wellcome Trust, UK



Dr Anthony S Fauci

Director, National Institute of Allergy and Infectious Diseases, USA



Ms Henrietta Fore

Executive Director, UNICEF



Dr George F. Gao

Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China



H.E. Sigrid Kaag

Minister for Foreign Trade and Development Cooperation, The Netherlands



Prof Ilona Kickbusch

Chair of the International Advisory Board of the Global Health Centre at the Graduate Institute of International Development Studies, Geneva



Dr Ngamije M. Daniel

Minister of Health, Republic of Rwanda

Alle Referenten



Hermann Gröhe

Stellvertretender Vorsitzender der CDU/CSU-Bundestagsfraktion |
Beauftragter für Kirchen und Religionsgemeinschaften



Ralph Brinkhaus

Vorsitzender der CDU/CSU-Fraktion im Deutschen Bundestag



Dr. Angela Merkel

Bundeskanzlerin der Bundesrepublik Deutschland



Prof. Ilona Kickbusch PHD

Graduate Institute of International and Development Studies
Geneva

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



Dr. Tedros Adhanom Ghebreyesus

Generaldirektor der Weltgesundheitsorganisation

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



Prof. Dr. Christian Drosten

Institut für Virologie Charité – Universitätsmedizin Berlin

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



Prof. Dr. Clarissa Prazeres da Costa

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene |
Technische Universität München

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



Joe Cerrell

Geschäftsführender Direktor Globale Politik | Bill and Melinda Gates
Foundation

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



Prof. Jeremy Farrar

Direktor Wellcome Trust

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen



Dr. Georg Kippels



Jens Spahn

Bundesminister für Gesundheit

8. Mai 2019

CDU Veranstaltung – Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

<https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten>

Global Health Hub Germany

The Global Health Hub Germany is a network that aims to bring together all actors interested in Global Health. The Hub wants to promote exchange, initiate new partnerships, support cooperation and innovative approaches - across sectors and stakeholder groups.

Membership is open to both individuals and organizations from all areas and sectors involved in Global Health - stakeholders from science, the private sector, civil society and politics, as well as from the health, environment, climate, food, agriculture, education and research sectors.


The Hub was inaugurated by Minister of Health Jens Spahn in February 2019 with a kick-off event at the Federal Ministry of Health. The Ministry of Health is providing funding for three years (2019-2021) for the set-up of the Hub and the establishment of the office.

Since the kick-off, the number of members has increased continuously: more than 1150 individuals and organizations have by now registered to make new contacts, exchange views on current issues and work together.

To promote cooperation and exchange, the Hub offers various possibilities and formats:

- Members can collaborate in cross-sectoral and cross-actor working groups on issues of their choice. Approximately 20 working groups have already been established on topics such as "Universal health coverage through digital technology", "Climate and Health" or "Global Mental Health". In the "Virtual Working Space", in the members only area of the website, interested members can join the already existing working groups to collaborate and discuss. Your topic is not included yet? No problem, you can suggest a new working group and search for fellow members who are interested in working on the same topic.
- With different types of events the Hub promotes regular exchange between members. In addition to face-to-face events, such as the annual Global Health Talk, webinars are held regularly to discuss current topics or present the work of the members.
- All registered members can be found in the member database in the members only area of the website. There you can search for experts on specific topics or from specific stakeholder groups. You can send networking requests, exchange views and discuss via the website by using the chat feature.
- In an interactive forum all members can informally exchange information, ask questions or give advice.

<https://www.globalhealthhub.de/index.php/en/content/about-hub>




The screenshot shows the website of the Global Health Hub Germany. The header includes the logo, navigation links (ABOUT, EVENTS CALENDAR, NEWS, WORKING GROUPS), and user options (LOGIN, REGISTER, EN, DE). The main heading is "Steering Committee". Below it, a paragraph states: "The Steering Committee is responsible for the strategic planning, further development and direction of the Hub. The Steering Committee consists of 16 representatives who on a parity basis represent the stakeholder groups science, private sector, civil society and youth as well as think tanks, foundations, the parliament and international organizations." A section titled "Foundations" lists two members: Caroline Schmutte, Wellcome Trust, and Tobias Kahler, Bill & Melinda Gates Foundation.

Foundations

- Caroline Schmutte, Wellcome Trust
- Tobias Kahler, Bill & Melinda Gates Foundation

<https://www.globalhealthhub.de/en/content/steering-committee>

Global Health Hub Germany



Advisory Board on Global Health (Germany)

Jens Spahn

29. Juli 2019

<https://www.globalhealthhub.de/en/news/international-advisory-board-germanys-opportunities-shaping-global-health>



29 JUL. 2019 | GLOBAL | BY: JULIA SCHMIDT

Event 201

18. Oktober 2019

<https://www.centerforhealthsecurity.org/event201/>

Players:

<https://www.centerforhealthsecurity.org/event201/players/index.html>

Video posted by John Hopkins University:

<https://www.youtube.com/watch?v=AoLw-Q8X174&list=PL9-oVXQX88esnrhaiuRdXGG7XOVYB9Xm>



Event 201 was supported by funding from the Open Philanthropy Project.

<https://www.centerforhealthsecurity.org/event201/about>



Latoya Abbott



Sofia Borges



Brad Connett



Christopher Elias



Tim Evans



George Gao



Avril Haines



Jane Halton



Matthew Harrington



Martin Knuchel



Eduardo Martinez



Stephen Redd



Hasti Taghi



Adrian Thomas



Lavan Thiru

Berlin, Germany

#WHS2021 SPEAKERS

[See more](#)

<https://www.worldhealthsummit.org/summit/speakers.html>



WORLD HEALTH SUMMIT

OCTOBER 24-26, 2021
BERLIN, GERMANY & DIGITAL
SCIENCE · INNOVATION · POLICIES

SUMMIT 2021

ABOUT

PARTNERS

INITIATIVES

M8 ALLIANCE

NEWSROOM

COMMUNITY

COVID-19 PLATFORM

REGIONAL MEETINGS

[Home](#) > [Partners](#) > [Sponsoring Partners](#)

SPONSORING AND SUPPORTING PARTNERS

STRATEGIC PARTNERS






MAJOR PARTNERS













GENERAL PARTNERS









SUPPORTING PARTNERS


















NEWSLETTER

Get insights on global health, read about M8 Alliance and community activities, and stay up-to-date with the World Health Summit program: Sign up for our newsletter [here](#)

PATRONS 2021

The World Health Summit is traditionally held under the patronage of:

Angela Merkel

Chancellor of the Federal Republic of Germany

Emmanuel Macron

President of the French Republic

Ursula von der Leyen

President of the European Commission

Tedros Adhanom Ghebreyesus

Director-General of the World Health Organization (WHO)

KAMPALA DECLARATION

The World Health Summit Regional Meeting in Uganda ended with the Kampala Declaration on COVID-19 Vaccine Equity, signed by the Director-General of WHO, the President of Uganda, several ministers from Africa, the M8 Alliance, and the World Health Summit.

Find the declaration and all details on the [Regional Meeting here](#)



M8 ALLIANCE EXPERT MEETINGS 2021

Next Webinar: November 30, 2021


More information

WORLD HEALTH SUMMIT PRESIDENT

Axel R. Pries, Dean of Charité - Universitätsmedizin Berlin is World Health Summit President since 2021.

[Read more](#)

Jens Spahn, CDU, Bundesgesundheitsminister



<https://www.tagesspiegel.de/politik/privater-immobiliendeal-des-gesundheitsministers-jens-spahn-ist-seiner-verantwortung-nicht-gerecht-geworden/26741038.html>

<https://www.spiegel.de/politik/deutschland/jens-spahn-villa-in-berlin-dahlem-kostete-4-125-millionen-euro-a-d8a665b4-4746-4ce8-898b-a1eb6713b0dd>

https://lobbypedia.de/wiki/Jens_Spahn

https://de.wikipedia.org/wiki/Jens_Spahn <https://cdn.businessinsider.de/wp-content/uploads/2021/04/Liste.pdf> (Jens Spahn - please see page 4 and 5)

PANORAMA

CORONAVIRUS-LIVETICKER CORONAVIRUS: ALLE KARTEN UND ZAHLEN

WELT: PETER PIOT

„Ohne einen Coronavirus-Impfstoff werden wir nie wieder normal leben können“

Veröffentlicht am 13.05.2020 | Lesezeit: 4 Minuten

Von Cornelia Karin Hendrich Redakteurin



Peter Piot warnt: Das Coronavirus sei eine "lebensverändernde Erfahrung".
Quelle: FABRICE COFFRANT/ATP via Getty Images

Einen Hauch des Todes habe er bei seiner Begegnung mit Covid-19 gespürt, sagt Peter Piot. Der Arzt und Wissenschaftler berät Ursula von der Leyen, zuletzt war er selbst an Corona erkrankt. Ohne Impfstoff werde es kein normales Leben mehr geben.

Der Wissenschaftler und Arzt Peter Piot, Mitentdecker des Ebola-Virus, hat nach seiner eigenen Erkrankung mit Covid-19 vor Langzeitfolgen des neuartigen Coronavirus für viele Menschen gewarnt. Der vielfach ausgezeichnete Forscher, der auch Sonderberater der Präsidentin der EU-Kommission, Ursula von der Leyen, ist, sagte: „Es wird weltweit Hunderttausende von Menschen geben, möglicherweise mehr, die für den Rest ihres Lebens Behandlungen wie eine Dialyse benötigen.“

<https://www.welt.de/vermishtes/plus207946977/Peter-Piot-Ohne-einen-Coronavirus-Impfstoff-werden-wir-nie-wieder-normal-leben-koennen.html>

European Commission

Home > Research and Innovation > Events > Upcoming events > European Research and Innovation Days > Speakers > Peter Piot

Peter Piot

Peter Piot is the Director of the London School of Hygiene & Tropical Medicine and Special Advisor to the President of the European Commission on COVID-19. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008. He co-discovered the Ebola virus in 1976 and conducted pioneering research on HIV/AIDS.

Organization
London School of Hygiene & Tropical Medicine

Position
Director

See all speakers

Share this page

Twitter Facebook LinkedIn Email More share options

European Commission website

More information on:
Strategy
About the European Commission
Business, Economy, Euro

Aid, Development cooperation, Fundamental rights
Food, Farming, Fisheries
EU regional and urban development

<https://ec.europa.eu/research-and-innovation/en/events/upcoming-events/research-innovation-days/speakers/peter-piot>

https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_Piot_Peter_EN.pdf

Menu

Search

Home > Ideas > Media Center > Dr. Peter Piot joins Foundation as a Senior Fellow

Dr. Peter Piot Joins Foundation as a Senior Fellow - Bill & Melinda Gates Foundation

Media contact

Phone: +1.206.709.3400
Email: media@gatesfoundation.org

SEATTLE -- The Bill & Melinda Gates Foundation announced today that Peter Piot, M.D., Ph.D., has joined the foundation's Global Health Program as a senior fellow until April 30. A distinguished academic and accomplished leader in the global effort to fight HIV/AIDS, Piot served from 1995 to 2008 as the founding executive director of the Joint United Nations Program on HIV/AIDS (UNAIDS).

"Peter is a rigorous scientist and a passionate advocate for global health," said Dr. Tachi Yamada, president of the foundation's Global Health Program. "The foundation and our partners will benefit greatly from his deep experience and his insight into the health challenges facing developing countries."

As a senior fellow, Piot will advise the foundation on its global health strategy, including its support for efforts to fight HIV/AIDS and other infectious diseases.


"I am encouraged by the growing enthusiasm and support for improving health in the developing world," said Dr. Piot. "The Gates Foundation has played a central role in making this progress possible, and I look forward to working closely with my colleagues at the foundation to build on this momentum."

While at UNAIDS, Piot built a broad international coalition against the global HIV/AIDS epidemic, including both governments and civil society groups. He successfully advocated for increased funding for and attention to the epidemic. Global investments to fight HIV/AIDS grew from \$250 million in 1996 to \$10 billion in 2007.


Piot holds a medical degree from the University of Ghent in Belgium. In 1976, while in Zaire pursuing his Ph.D. in microbiology, he co-discovered the Ebola virus. Piot has held several academic positions and pioneered a series of collaborative programs in sub-Saharan Africa, including Project SIDA in Kinshasa, Zaire, the first international program on HIV in Africa.

<https://www.gatesfoundation.org/ideas/media-center/press-releases/2009/01/dr-peter-piot-joins-foundation-as-a-senior-fellow>

Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA



Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA, Lothar Wieler, Christian Drosten



Hans-Ulrich Holtherm - Neu im Bundesgesundheitsministerium – 03/2020

aerzteblatt.de

/ Ärzteblatt / cme / Ärztstellen / Studieren / English Edition

Home Archiv News Themen DÄ plus Politik Medizin

Archiv > Deutsches Ärzteblatt > 11/2020 > Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

PERSONALIEN

Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

Dtsch Arztebl 2020; 117(11): A-557 / B-481

Beerheide, Rebecca



Artikel

Briefe & Kommentare

Statistik

Seit dem 1. März leitet Generalarzt Dr. med. Hans-Ulrich Holtherm (55) die im Bundesgesundheitsministerium (BMG) neu geschaffene Abteilung 6 „Gesundheitsschutz, Gesundheitssicherheit, Nachhaltigkeit“. In der Abteilung gibt es zwei Unterabteilungen mit jeweils fünf Fachreferaten, dazu zählen Referate zum nationalen und internationalen Krisenmanagement.

„Dr. Hans-Ulrich Holtherm verbindet durch seine langjährigen Erfahrungen die Themen Gesundheit und Sicherheit im gesamtgesellschaftlichen Ansatz und ist daher Sinnbild für die neue Abteilung 6“, heißt es zur Personale aus dem Ministerium. Der Kommandeur und Ärztliche Direktor des Bundeswehrkrankenhauses Ulm, bei dem er seinen Dienst erst im Januar 2020 antrat, sei Experte in Fragen des öffentlichen Gesundheitsdienstes im Inland sowie durch Erfahrungen mit der Bundeswehr im Ausland auch „sachkundig in der Krisenreaktion und -prävention“, so das BMG. Die Gründung dieser neuen Abteilung wurde schon 2019 beschlossen.



Hans-Ulrich Holtherm,
Foto: Bundeswehr

Anzeige

Holtherm war bei Auslandseinsätzen im Irak, Afghanistan, im Kongo, in Dschibuti und im Kosovo. Der Generalarzt war bereits 2009 im Zuge der H1N1-Pandemie von der Bundeswehr abgeordnet in das BMG und gehörte auch 2014 dem ressortübergreifenden Ebola-Krisenstab an. 1964 in Rheine geboren, trat er 1983 in die Bundeswehr ein und studierte als Sanitätsoffiziersanwärter in Münster Humanmedizin. Er ist Allgemeinmediziner, Facharzt für Öffentliches Gesundheitswesen mit Zusatzqualifikationen in Tropen-, Flug- und Betriebsmedizin. Rebecca Beerheide

<https://www.aerzteblatt.de/archiv/213019/Hans-Ulrich-Holtherm-Neu-im-Bun%C2%ADdes%C2%ADge%C2%ADsund%C2%ADheits%C2%ADmi%C2%ADnis%C2%ADter%C2%ADium>

https://de.wikipedia.org/wiki/Hans-Ulrich_Holtherm

Paul Zubeil - Neu im Bundesgesundheitsministerium – 02/2021

Paul Zubeil

Ehemann von Hendrik Streeck tritt Stelle im Gesundheitsministerium an

8. Februar 2021 um 16:07 Uhr | Lesedauer: 5 Minuten



Das Bundesgesundheitsministerium hat seinen Sitz in Bonn. Foto: Benjamin Westhoff

Bonn. Der Ehemann des Bonner Virologen Hendrik Streeck, Paul Zubeil, hat am Montag eine Stelle im Bundesgesundheitsministerium am Dienort Bonn angetreten. Er ist dort Unterabteilungsleiter für europäische und internationale Angelegenheiten.

https://ga.de/bonn/stadt-bonn/partner-von-hendrik-streeck-paul-zubeil-arbeitet-fuer-das-bundesgesundheitsministerium_aid-56131801



Unsere Kollaborationen in den Bereichen Infektionskrankheiten und seltene Erkrankungen

Genevant

- Seit 2018 Co-Entwicklungs- und -Kommerzialisierungspartner für fünf mRNA-Proteinersatztherapien bei seltenen Erkrankungen; 50:50 globale Kosten- und Gewinnaufteilung
- Fünf exklusive Onkologie-LNP-Lizenzen für BioNTech. Genevant ist berechtigt, bedeutende kommerzielle Meilensteine für die Onkologie-Lizenzen zu erhalten

Pfizer

- Seit 2018 bestehende Lizenzierungsvereinbarung zur gemeinsamen Entwicklung eines prophylaktischen Grippeimpfstoffs auf mRNA-Basis (BNT161)
- Vorabzahlung, Kapitalinvestition und erste Meilensteinzahlungen in Höhe von 120 Mio. \$
- Bis zu 325 Mio. \$ an möglichen weiteren Meilensteinzahlungen
- Lizenzgebühren auf weltweiten Absatz auf weltweiten Nettoumsatz im Falle einer Marktzulassung

University of Pennsylvania (UPenn)

- Seit 2018 strategische Forschungs- und Entwicklungskooperation mit der exklusiven Option, mRNA-Immuntherapien zur Behandlung von bis zu zehn Indikationen von Infektionskrankheiten zu entwickeln und zu vermarkten

- Unterstützung der Forschungsaktivitäten seitens BioNTech mit 20 Mio. \$

- UPenn führt die präklinischen Studien durch

- BioNTech behält die Option, die mRNA-Impfstoffkandidaten für die klinische Entwicklung zu lizenzieren

Bill & Melinda Gates Foundation

- Seit 2019 Forschungs- und Entwicklungsvereinbarung im Bereich HIV und Tuberkulose (TB) sowie bis zu drei weiteren Infektionskrankheiten

- 55 Mio. \$ als Equity-Investition in die Entwicklung weiterer Strategien zur Prävention und/oder Behandlung von HIV und TB

- Zuschüsse in Höhe von bis zu 45 Mio. \$ zur Finanzierung zusätzlicher Aktivitäten in bis zu drei weiteren Projekten im Bereich Infektionskrankheiten innerhalb der ersten fünf Jahre der Zusammenarbeit

Epitop, welches in Bauchspeicheldrüsenkrebs und anderen gastrointestinalen Krebsarten exprimiert wird und dort eine Rolle bei der Tumordrüsion und Metastasenbildung spielt.

Im Juni 2019 gab BioNTech den Start der klinischen Entwicklung von Produktkandidat DuoBody®-PD-L1x4-1BB bekannt. PD-L1x4-1BB ist ein bi-spezifischer Antikörper, der gemeinsam mit Gen-mab A/S entwickelt wird. Im Rahmen der Phase-1/2a-Studie wird der bi-spezifische Antikörper in Patienten mit metastasierenden oder chirurgisch nicht entfernbaren soliden Tumoren getestet, die nicht mit der Standardtherapie behandelt werden können. Der DuoBody®-PD-L1x4-1BB ist der erste gemeinsam entwickelte Produktkandidat, der die klinische Phase erreicht. Die Kosten und Gewinne, die im Zuge der Partnerschaft anfallen, werden im Verhältnis 50 zu 50 geteilt. Ziel der 2015 unterzeichneten und 2016 um weitere Zielstrukturen und Technologien erweiterten Zusammenarbeit ist die Entwicklung und Vermarktung mehrerer neuartiger bi-spezifischer Antikörper mit überle-gener in-vivo-Wirksamkeit, die das Immunsystem spezifisch gegen Krebszellen aktivieren.

Im September 2019 hat BioNTech eine Partner-schaft mit der Bill & Melinda Gates Stiftung für die Entwicklung von HIV- und Tuberkulose Impfstoffen bekanntgegeben. Im Rahmen dieser Vereinbarung hat BioNTech im September 2019 eine erste Kapitalinvestition in Höhe von 49.864 T€ (55.000 T\$) erhalten. Die Finanzierung dient der Entwicklung von präklinischen Impfstoffen sowie Immuntherapiekandidaten für HIV- und Tuberku-lose Infektionen, die präventiv eingesetzt werden und im Fall von HIV eine dauerhafte Remission ohne antiretrovirale Therapie ermöglichen sollen. Durch zusätzliche zukünftige Finanzierungsverein-

barungen könnten sich die Gesamtinvestitionen der Gates Stiftung auf bis zu 100.000 T\$. belaufen. In diesem Fall wird dieses Kapital für die klinische Entwicklung von Produktkandidaten sowie der Initiierung neuer Projekte in diesem Indikations-bereich verwendet werden.

Finanzierung

KAPITALERHÖHUNG SERIES B

Im Juni und August 2019 hat BioNTech die Series-B-Finanzierungsrunde abgeschlossen, um seine individualisierte Krebsmedizinpipeline weiterzuentwickeln. Hierbei handelt es sich um eine der größten Einzelfinanzierungen eines privaten europäischen Biotechnologieunterneh-mens. In diesem Zusammenhang gab BioNTech insgesamt 12.465.288 Stammaktien (mit Aus-nahme von 5.524.506 Stammaktien, die an einen in Hongkong ansässigen Investor ausgegeben und anschließend aufgrund keiner Gegenleistung wie-der an BioNTech übertragen wurden; diese Aktien werden als eigene Anteile gehalten) an neue sowie bestehende Aktionäre zu einem Preis von 18,10 \$ pro Aktie für einen Gesamterlös von 198.548 T€ (225.622 T\$) aus. Die Kapitalerhöhung erhöhte das gezeichnete Kapital um 17.990 T€ und die Kapital-rücklage um 186.390 T€ sowie die Erfassung von eigenen Anteilen in Höhe von 5.525 T€.

BÖRSENGANG („INITIAL PUBLIC OFFERING – IPO“)

Am 10. Oktober 2019 erhöhte BioNTech in Ver-bindung mit dem Börsengang das gezeichnete Kapital um 10.000 T€. American Depositary Shares (ADS), die Stammaktien repräsentieren, wurden an der Nasdaq Global Select Market zu einem Preis von 15,00 \$ angeboten. Am 6. November 2019 erhöhte BioNTech das gezeichnete Kapital um weitere 517 T€ durch die Ausübung der im Zusammenhang mit dem


Die nachstehende Tabelle gibt eine Übersicht zu 2019 und 2018 an Vorstandsmitglieder ausgege- den Aktienoptionen, die in den Geschäftsjahren ben wurden.

	Zeitpunkt der Ausgabe ¹	Anzahl der den Aktienoptionen zugrunde liegen- den Stammaktien ⁴	Ausübungspreis (€)	Ablauf der Möglichkeit zur Optionsausübung
Prof. Dr. Ugur Sahin	15.11.2018	1.830.348	10,14	17.9.2026
	10.10.2019 ²	4.374.963	13,60	11.10.2029
Sean Marett	15.11.2018	610.110	10,14	17.9.2026
Dr. Sierk Poetting	15.11.2018	610.110	10,14	17.9.2026
Dr. med. Özlem Türeci	15.11.2018 ³	1.952.334	10,14	17.9.2026


¹ Wenn nicht anders angegeben, werden alle Optionen am 16. September 2022 unverfallbar.
² Die Option wird jährlich in gleichen Raten nach vier Jahren, jeweils am 10. Oktober in den Jahren 2020, 2021, 2022 und 2023, unverfallbar.
³ Die Optionen wurden am 16 März 2019 unverfallbar, gleichwohl kann die Ausübung erst ab dem 16. September 2022 erfolgen.
⁴ Die Anzahl der Stammaktien bildet den Effekt der Kapitalerhöhung aufgrund eines Aktiensplits von 1:18 ab, der Am 8. September 2019 mit der Eintragung im Handelsregister wirksam wurde.

Link Analysis


Simple extract of links between Gates Foundation and other NGOs /GOVs



WHO – World Health Organization



CARB-X



GIZ



Bill & Melinda Gates Foundation

Mitglied

Financed \$6,150,971 Finance Bill & Melinda Gates Foundation



SEEK Development, Strategic and...

Client

Client

Client



BMZ - Federal Ministry for Econ...

??



GIZ Deutsche Gesellschaft für I...

Unterstützung and investors



Agenda 2030




PharmAccess Foundation

Mitglied




Global Health Hub Germany

WGHA - Washington Global Health Alliance




Almost all of these individuals' employers receive donations from the Gates Foundation.


WGHA - Washington Global
Health Alliance
AND
Board Members of
University of Washington -
Department of Health




MMV




Adjuvant Capital




Merck




Merck + Jule Louise Gerberding (direct connections)







Johnson & Johnson




IVI - International Vaccine Institute




ID2020







ONE




IFPMA - International Federation of Pharmaceutical Manufacturers & Associations




PharmAccess Foundation







CGD - Center for Global Development



NTI - Nuclear Threat Initiative (1 Level)



NTI - Nuclear Threat Initiative
+ Direct Linked Persons (1 Level)



NTI - Nuclear Threat Initiative (Additional Information)

<https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/>

<https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/biosecurity-innovation-and-risk-reduction-initiative-launch/>


[https://media.nti.org/documents/Biosecurity Innovation and Risk Reduction.pdf](https://media.nti.org/documents/Biosecurity_Innovation_and_Risk_Reduction.pdf)

[https://media.nti.org/documents/NTI BIO TTX RPT FINAL.pdf](https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf)


[https://media.nti.org/documents/NTI Paper A Spreading Plague FINAL 061119.pdf](https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf)

[https://media.nti.org/documents/Participants List TTX on Deliberate Bio Event 2019 MSC 2.14 FINAL.pdf](https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf)


CSIS - Center for Strategic and International Studies / Strengthening America's Health Security




CSIS - Center for Strategic and International Studies / Strengthening America's Health Security




GVP - Global Virome Project - 1 Level Connections




GVP - Global Virome Project (Level 2 Connections)




METABIOTA (Level 2 Connections)




IHME - The Institute for Health Metrics and Evaluation



IHME - The Institute for Health Metrics and Evaluation incl. direct connections of Members



DARPA




Pentagon tasks Pfizer with radically rethinking vaccine development - <https://www.fiercepharma.com/r-d/pentagon-tasks-pfizer-radically-rethinking-vaccine-development> (2013-12-09)

BARDA - Rapidly advancing a Zika mRNA vaccine / DARPA – Advancing mRNA therapies and vaccines for biodefense


- <https://www.modernatx.com/ecosystem/strategic-collaborators/mrna-strategic-collaborators-government-organizations> (09/2016 & 10/2013)

Selected Views


Peter Piot
Lothar Wieler
Victor Dzau
Georg F Gao
Jeremy Ferrar
Christian Drosten
Ralph S. Baric
Peter Daszak




CDC - 1 Level



CDC - Director / Former
Director - 1 Level



Contributors of selected documents



1 - Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 <https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930418-9>

2 - Leopoldina-Stellungnahmen zur Coronavirus-Pandemie (2020) <https://www.leopoldina.org/publikationen/detailansicht/publication/leopoldina-stellungnahmen-zur-coronavirus-pandemie-2020/>

3 - Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020 <https://apps.who.int/iris/rest/bitstreams/1266309/retrieve>

4 - Document - The Global Virome Project https://www.who.int/bulletin/online_first/BLT.17.205005.pdf

5 - Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR (2020-01-13) https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2